These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6978286)

  • 1. Further studies on the mitogenic and immune-modulating effects of plasminogen activator.
    Wainberg MA; Israel E; Margolese RG
    Immunology; 1982 Apr; 45(4):715-20. PubMed ID: 6978286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator is an apparent lymphocyte mitogen.
    Cohen SD; Israel E; Spiess-Meier B; Wainberg MA
    J Immunol; 1981 Apr; 126(4):1415-20. PubMed ID: 6259259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on interactions between plasminogen activator-containing fluids and avain and murine lymphocytes.
    Wainberg MA; Cohen SD
    Dev Comp Immunol; 1981; 5(4):649-60. PubMed ID: 6274714
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of responding cells in oxidative mitogen stimulation. I. Ia+ cells and Ly-1+2+ cells are required for the proliferative response.
    Phillips ML; Wettstein PJ; O'Brien RL; Parker JW; Frelinger JA
    J Immunol; 1980 Jun; 124(6):2693-9. PubMed ID: 6246169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
    De Petro G; Copeta A; Barlati S
    Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
    Colombi M; Bellotti D; De Petro G; Barlati S
    Invasion Metastasis; 1995; 15(1-2):22-33. PubMed ID: 7672929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering.
    Gundersen D; Trân-Thang C; Sordat B; Mourali F; Rüegg C
    J Immunol; 1997 Feb; 158(3):1051-60. PubMed ID: 9013942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and release of plasminogen activator by lymphoid cell lines of malignant origin and its effect on lymphocyte cytotoxicity.
    Sundar SK; Bergeron J; Menezes J
    Exp Biol; 1985; 43(4):277-85. PubMed ID: 2989001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of NK cell activation: relationship between Qa5+ NK cells and lymphocytes.
    Chun M; Fernandes G; Hoffmann MK
    J Immunol; 1981 Jan; 126(1):331-4. PubMed ID: 7451974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective removal of T cell function from mouse lymphocyte suspensions by treatment with normal guinea pig serum.
    Kierszenbaum F; Budzko DB; Miller HC
    J Immunol; 1980 Apr; 124(4):1599-602. PubMed ID: 6988503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
    Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
    Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activation by normal B lymphocytes, a function associated with the cell membrane.
    Maillard JL; Favreau C
    J Immunol; 1981 Mar; 126(3):1126-30. PubMed ID: 6161960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
    Wilson MJ; Ludowese C; Sinha AA; Estensen RD
    Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
    Lijnen HR; Wagner EF; Collen D
    Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitogenic activity of purified capsular polysaccharide A from Bacteroides fragilis: differential stimulatory effect on mouse and rat lymphocytes in vitro.
    Brubaker JO; Li Q; Tzianabos AO; Kasper DL; Finberg RW
    J Immunol; 1999 Feb; 162(4):2235-42. PubMed ID: 9973499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor.
    Fibbi G; Caldini R; Chevanne M; Pucci M; Schiavone N; Morbidelli L; Parenti A; Granger HJ; Del Rosso M; Ziche M
    Lab Invest; 1998 Sep; 78(9):1109-19. PubMed ID: 9759655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
    Fowler B; Mackman N; Parmer RJ; Miles LA
    Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells.
    Yee JA; Yan L; Dominguez JC; Allan EH; Martin TJ
    J Cell Physiol; 1993 Dec; 157(3):528-34. PubMed ID: 8253864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.